Nifekalant is an antagonist at potassium channels that is clinically used to treat ventricular tachyarrhythmia; it is a class III anti-arrhythmic that increases the time course of myocardial repolarization and may prolong the QT interval. Nifekalant may also be used to treat atrial fibrillation, as it increases right atrial monophasic action potential duration and the atrial effective refractory period in subjects with atrial fibrillation.
| Cas No. | 130656-51-8 |
|---|---|
| Purity | ≥98% |
| Formula | C19H27N5O5 • HCl |
| Formula Wt. | 441.91 |
| Chemical Name | 6-[2-[(N-2-Hydroxyethyl)-3-(4-nitrophenyl)-propyl- amino(ethylamino)-1,3-dimethyl-1H,3H - pyrimidine- 2,4-dione monohydrochloride |
| IUPAC Name | 6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione;hydrochloride |
| Synonym | MS 551 |
| Appearance | Cream-colored crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | N3422 MSDS PDF |
|---|---|
| Info Sheet | N3422 Info Sheet PDF |
Harayama N, Nihei SI, Nagata K, et al. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. J Anesth. 2014 Jan 5. [Epub ahead of print]. PMID: 24389941.
Sonoda K, Watanabe I, Ohkubo K, et al. Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation. Int Heart J. 2013;54(5):279-84. PMID: 24097216.
Pantazopoulos IN, Troupis GT, Pantazopoulos CN, et al. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011 Jun 26;3(6):169-76. PMID: 21772943.
